GlycoMimetics Announces Publication of Preclinical Data Showing Drug Candidate GMI-1271 Reduces Inflammatory Responses After Heart Attack
- Research shows effectiveness in stabilizing atherosclerotic plaques, reducing risk of further injury due to reduced blood flow
In the study, researchers demonstrated a wider range of potential clinical applications of the E-selectin antagonist GMI-1271, which is currently being evaluated as a potential treatment for acute myelogenous leukemia (AML) in a Phase 1/2 clinical trial.
"The results in this animal model of myocardial infarction and
atherosclerosis demonstrate both the biological activity of GMI-1271 and
the possible broader uses of an E-selectin antagonist. While
Myocardial infarctions are often triggered by unstable atherosclerotic
plaque material, the growth of which is initiated by the production and
infiltration of inflammatory cells through the action of E-selectin. The
study, conducted at
About
Forward-Looking Statements
This press release contains forward-looking statements regarding
GlycoMimetics' planned activities with respect to the clinical
development of its drug candidate GMI-1271. Actual results may differ
materially from those indicated by such forward-looking statements as a
result of various important factors, including the availability and
timing of data from ongoing clinical trials, the uncertainties inherent
in the initiation of future clinical trials, whether interim results
from a clinical trial will be predictive of the final results of the
trial or results of early clinical trials will be indicative of the
results of future trials, expectations for regulatory approvals,
availability of funding sufficient for GlycoMimetics' foreseeable and
unforeseeable operating expenses and capital expenditure requirements,
other matters that could affect the availability or commercial potential
of GlycoMimetics' drug candidates and other factors discussed in the
"Risk Factors" section of GlycoMimetics' Annual Report on Form 10-K that
was filed with the
View source version on businesswire.com: http://www.businesswire.com/news/home/20160816005628/en/
Investor Contact:
sannes@annesassociates.com
or
Media
Contact:
jamielacey@presscommpr.com
Source:
News Provided by Acquire Media